Zokinvy

Active Ingredient(s): Lonafarnib
FDA Approved: * November 20, 2020
Pharm Company: * EIGER BIOPHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zokinvy Overview

Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older.[2][3] The most common side effects included nausea vomiting, diarrhea, infection, decreased appetite and fatigue.[2] Lonafarnib was approved for medical use in the United States in November 2020...

Read more Zokinvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lonafarnib

Recent Zokinvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Other drugs which contain Lonafarnib or a similar ingredient: (1 result)

• LONAFARNIB